Search research articles
Contact Us
Filters
Showing results (111-120 of 525) with videos related to
Page
of 53
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 7, 2011
Complete remission of Waldenström macroglobulinemia with azacitidine and rituximab
Lukas Weiss, Thomas Melchardt, Daniel Neureiter, et al.
The Journal of Steroid Biochemistry and Molecular Biology
|
May 4, 2010
PLZF/ZBTB16, a glucocorticoid response gene in acute lymphoblastic leukemia, interferes with glucocorticoid-induced apoptosis
Muhammad Wasim, Michela Carlet, Muhammad Mansha, et al.
Plos One
|
November 10, 2018
Novel models for prediction of benefit and toxicity with FOLFIRINOX treatment of pancreatic cancer using clinically available parameters
Konstantin Schlick, Teresa Magnes, Lukas Ratzinger, et al.
Blood
|
July 11, 2006
Expression levels of CD38 in T cells predict course of disease in male patients with B-chronic lymphocytic leukemia
Inge Tinhofer, Gabriele Rubenzer, Claudia Holler, et al.
Acta Dermato-Venereologica
|
December 10, 2009
Vincristine, idarubicin, dexamethasone and thalidomide in scleromyxoedema
Martin Laimer, Konrad Namberger, Cesare Massone, et al.
Clinical Colorectal Cancer
|
May 8, 2019
Regorafenib Is Associated With Increased Skeletal Muscle Loss Compared to TAS-102 in Metastatic Colorectal Cancer
Florian Huemer, Verena Schlintl, Stefan Hecht, et al.
Leukemia & Lymphoma
|
February 17, 2016
Low Beclin-1 expression predicts improved overall survival in patients treated with immunomodulatory drugs for multiple myeloma and identifies autophagy inhibition as a promising potentially druggable new therapeutic target: an analysis from The Austrian Myeloma Registry (AMR)
Wolfgang Willenbacher, Shanmugapriya Thangavadivel, Richard Greil, et al.
Investigational New Drugs
|
December 23, 2014
A phase 1 dose escalation study of BI 831266, an inhibitor of Aurora kinase B, in patients with advanced solid tumors
Christian Dittrich, Michael A Fridrik, Robert Koenigsberg, et al.
Breast Cancer Research and Treatment
|
April 2, 2020
Long-term (up to 16 months) health-related quality of life after adjuvant tailored dose-dense chemotherapy vs. standard three-weekly chemotherapy in women with high-risk early breast cancer
Yvonne Brandberg, Hemming Johansson, Mats Hellström, et al.
Cancers
|
October 3, 2020
Hospitalizations and Clinical Outcome in Metastatic Colorectal Cancer During Regorafenib or TAS-102 Therapy
Florian Huemer, Gudrun Piringer, Verena Schlintl, et al.
Page
of 53
Search research articles
Search
Showing results (111-120 of 525) with videos related to
Sort By:
Page
of 53
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 7, 2011
Complete remission of Waldenström macroglobulinemia with azacitidine and rituximab
Lukas Weiss, Thomas Melchardt, Daniel Neureiter, et al.
The Journal of Steroid Biochemistry and Molecular Biology
|
May 4, 2010
PLZF/ZBTB16, a glucocorticoid response gene in acute lymphoblastic leukemia, interferes with glucocorticoid-induced apoptosis
Muhammad Wasim, Michela Carlet, Muhammad Mansha, et al.
Plos One
|
November 10, 2018
Novel models for prediction of benefit and toxicity with FOLFIRINOX treatment of pancreatic cancer using clinically available parameters
Konstantin Schlick, Teresa Magnes, Lukas Ratzinger, et al.
Blood
|
July 11, 2006
Expression levels of CD38 in T cells predict course of disease in male patients with B-chronic lymphocytic leukemia
Inge Tinhofer, Gabriele Rubenzer, Claudia Holler, et al.
Acta Dermato-Venereologica
|
December 10, 2009
Vincristine, idarubicin, dexamethasone and thalidomide in scleromyxoedema
Martin Laimer, Konrad Namberger, Cesare Massone, et al.
Clinical Colorectal Cancer
|
May 8, 2019
Regorafenib Is Associated With Increased Skeletal Muscle Loss Compared to TAS-102 in Metastatic Colorectal Cancer
Florian Huemer, Verena Schlintl, Stefan Hecht, et al.
Leukemia & Lymphoma
|
February 17, 2016
Low Beclin-1 expression predicts improved overall survival in patients treated with immunomodulatory drugs for multiple myeloma and identifies autophagy inhibition as a promising potentially druggable new therapeutic target: an analysis from The Austrian Myeloma Registry (AMR)
Wolfgang Willenbacher, Shanmugapriya Thangavadivel, Richard Greil, et al.
Investigational New Drugs
|
December 23, 2014
A phase 1 dose escalation study of BI 831266, an inhibitor of Aurora kinase B, in patients with advanced solid tumors
Christian Dittrich, Michael A Fridrik, Robert Koenigsberg, et al.
Breast Cancer Research and Treatment
|
April 2, 2020
Long-term (up to 16 months) health-related quality of life after adjuvant tailored dose-dense chemotherapy vs. standard three-weekly chemotherapy in women with high-risk early breast cancer
Yvonne Brandberg, Hemming Johansson, Mats Hellström, et al.
Cancers
|
October 3, 2020
Hospitalizations and Clinical Outcome in Metastatic Colorectal Cancer During Regorafenib or TAS-102 Therapy
Florian Huemer, Gudrun Piringer, Verena Schlintl, et al.
Page
of 53